CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure A population-based study of 92 clinically recognised risk factors for heart failure: co-occurrence, prognosis and preventive potential Association of Prior Left Ventricular Ejection Fraction With Clinical Outcomes in Patients With Heart Failure With Midrange Ejection Fraction Dilated cardiomyopathy: so many cardiomyopathies! The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Angiotensin–neprilysin inhibition versus enalapril in heart failure Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction

Expert Opinionhttps://academic.oup.com/eurheartj/article-abstract/41/39/3784/5686010?redirectedFrom=fulltext

JOURNAL:Eur Heart J. Article Link

Dilated cardiomyopathy: so many cardiomyopathies!

G Sinagra, PM Elliott, M Merlo et al. Keywords: DCM; LV; HF

ABSTRACT

The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk.